29 Mar 2016 07:00
29th March 2016
REDX PHARMA PLC
("Redx" or "the Company")
Grant of options under SAYE Scheme
Redx, the drug discovery and development company, has granted options over ordinary shares in the capital of the Company on 24 March 2016 to the following Director under Redx's new SAYE Share Option Scheme.
(Director) |
| Number of shares |
Phillip Tottey |
| 10,843 |
The Redx Pharma SAYE Share Option Scheme was formally launched on 26 February 2016 and made available to all permanent employees.
The options have an exercise price of 33.2 pence per share and are exercisable at the end of a three year savings contract ending 1 May 2019. The exercise price of 33.2p per share has been set according to HMRC rules, at a 20% discount to the market price at the time of the launch. A total of 1,145,350 share are under option for this scheme.
For further information please contact:
Redx Pharma Plc | T: 0151 706 4747 |
Neil Murray, Chief Executive Company website: redxpharma.com
|
|
Cantor Fitzgerald Europe (Nomad & Broker) | T: 020 7894 7000 |
Phil Davies / Michael Reynolds
|
|
KTZ Communications | T: 020 3178 6378 |
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson |
|
|
|
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.